Treatment of cutaneous leishmaniasis in travelers 2009. (Q37428084)

20 August 2017

1 reference

title

Treatment of cutaneous leishmaniasis in travelers 2009. (English)

1 reference

20 August 2017

cutaneous leishmaniasis

1 reference

Johannes A Blum

1

1 reference

PubMed ID

19335813

20 August 2017

Christoph F Hatz

series ordinal

2

1 reference

20 August 2017

1 March 2009

1 reference

Journal of Travel Medicine

20 August 2017

1 reference

20 August 2017

16

1 reference

20 August 2017

2

1 reference

20 August 2017

123-131

1 reference

Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit

20 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Treatment of cutaneous leishmaniasis among travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

New world cutaneous leishmaniasis in travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Cutaneous leishmaniasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Clinical features and diagnosis of 42 travellers with cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Cutaneous leishmaniasis in the returning traveler

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Miltefosine for new world cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Thrombocytopenia complicating sodium stibogluconate therapy for cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Oral miltefosine for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Treatment of New World cutaneous leishmaniasis with miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Placebo-Controlled Clinical Trial of Sodium Stibogluconate (Pentostam) versus Ketoconazole for Treating Cutaneous Leishmaniasis in Guatemala

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Mucosal leishmaniasis . Current scenario and prospects for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Out-patient parenteral antimicrobial therapy--a viable option for the management of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime). A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Low efficacy of azithromycin to treat cutaneous leishmaniasis in Manaus, AM, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Cutaneous leishmaniasis treated with azithromycin in a child

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Randomized, Double‐Blind Study of Stibogluconate Plus Human Granulocyte Macrophage Colony‐Stimulating Factor versus Stibogluconate Alone in the Treatment of Cutaneous Leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Immunotherapy for drug-refractory mucosal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Evaluation of CO laser efficacy in the treatment of cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

21 January 2018

Leishmaniasis in Germany

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Cutaneous leishmaniasis: an increasing threat for travellers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Changing pattern of imported cutaneous leishmaniasis in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open study in London

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1708-8305.2008.00286.X

10.1111/J.1708-8305.2008.00286.X

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19335813